文献速递造血干细胞移植与细胞治疗

利用正交IL-2/IL-2Rβ系统在体内选择性扩增调节性T细胞以预防急性移植物抗宿主病

Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo.
PubMed 文献 · Blood · 2023-01-01

该研究在小鼠主要组织相容性复合体不相合的移植物抗宿主病(GVHD)模型中,将表达正交白介素2受体β(oIL-2Rβ)的调节性T细胞(Treg)与oIL-2联合使用,结果较磷酸盐缓冲液(PBS)组提高了GVHD生存率、在体内选择性扩增了Treg并增强了抑制效应T细胞扩增的作用,同时在两种肿瘤模型中维持了移植物抗肿瘤(GVT)效应。

要点

  • oIL-2Rβ Treg联合oIL-2较PBS组提高了小鼠GVHD生存率。
  • oIL-2Rβ Treg联合oIL-2在体内选择性扩增Treg并增强对效应T细胞扩增的抑制。
  • oIL-2Rβ Treg在A20和MLL-AF9两种肿瘤模型中维持了GVT效应。

核心结论

  • oIL-2/oIL-2Rβ系统可在体内选择性扩增Treg,从而在保护GVHD的同时维持GVT效应。

研究设计与样本

  • 研究采用致死性照射的BALB/c小鼠接受C57BL/6(B6)小鼠T细胞去除的骨髓,单独或联合低细胞数量的B6Foxp3+GFP+ Treg或oIL-2Rβ转导Treg,建立主要组织相容性复合体不相合的GVHD模型。
  • 第2天注射B6活化T细胞(Tcons)诱导GVHD,受体每日接受PBS或oIL-2治疗14天,随后每周3次再治疗14天。
  • 在A20和MLL-AF9两种肿瘤模型中评估GVT效应。

主要发现

  • 与PBS组相比,oIL-2Rβ Treg联合oIL-2组小鼠的GVHD生存率提高。
  • 与PBS组相比,oIL-2Rβ Treg联合oIL-2组在体内选择性扩增Treg。
  • 与PBS组相比,oIL-2Rβ Treg联合oIL-2组在次级淋巴器官和肠道对Tcon扩增的抑制更强。
  • oIL-2Rβ Treg在A20和MLL-AF9两种肿瘤模型中维持了GVT效应。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative option for patients with hematological disorders and bone marrow (BM) failure syndromes. Graft-versus-host disease (GVHD) remains a leading cause of morbidity posttransplant. Regulatory T cell (Treg) therapies are efficacious in ameliorating GVHD but limited by variable suppressive capacities and the need for a high therapeutic dose. Here, we sought to expand Treg in vivo by expressing an orthogonal interleukin 2 receptor β (oIL-2Rβ) that would selectively interact with oIL-2 cytokine and not wild-type (WT) IL-2. To test whether the orthogonal system would preferentially drive donor Treg expansion, we used a murine major histocompatibility complex-disparate GVHD model of lethally irradiated BALB/c mice given T cell-depleted BM from C57BL/6 (B6) mice alone or together with B6Foxp3+GFP+ Treg or oIL-2Rβ-transduced Treg at low cell numbers that typically do not control GVHD with WT Treg. On day 2, B6 activated T cells (Tcons) were injected to induce GVHD. Recipients were treated with phosphate-buffered saline (PBS) or oIL-2 daily for 14 days, then 3 times weekly for an additional 14 days. Mice treated with oIL-2Rβ Treg and oIL-2 compared with those treated with PBS had enhanced GVHD survival, in vivo selective expansion of Tregs, and greater suppression of Tcon expansion in secondary lymphoid organs and intestines. Importantly, oIL-2Rβ Treg maintained graft-versus-tumor (GVT) responses in 2 distinct tumor models (A20 and MLL-AF9). These data demonstrate a novel approach to enhance the efficacy of Treg therapy in allo-HSCT using an oIL-2/oIL-2Rβ system that allows for selective in vivo expansion of Treg leading to GVHD protection and GVT maintenance.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ramos TL, Bolivar-Wagers S, Jin S, et al. Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo. Blood. 2023. PMID: 36564052. doi:10.1182/blood.2022018440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。